Weiter zum Inhalt
Toggle navigation
English
English
Favoritenliste (
0
)
(Voll)
Kontakt
Mein Konto
Abmeldung
Mein Konto
Suche
Erweiterte Suche
Suchverlauf
Struktursuche
Narrative Service
Drug Overviews
Info Guide
/vufind/Search/Results?lookfor=%22Janku%2C+F%22&type=Person&sort=year
/vufind/Search/Results?lookfor=%22Janku%2C+F%22&type=Person&sort=year
Search /vufind/Search2/Results?lookfor=%22Janku%2C+F%22&type=Person&sort=year
PubPharm (66)
1
Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST)
enthalten in:
Annals of oncology : official journal of the European Society for Medical Oncology
| 2024
von
Gouda, M.
|
Janku, F.
|
Wahida, A.
| +9
Wird geladen...
2
Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma
enthalten in:
ESMO open
| 2022
von
Janku, F.
|
Bauer, S.
|
Shoumariyeh, K.
| +7
Wird geladen...
3
Ultrasensitive detection of BRAF mutations in circulating tumor DNA of non-metastatic melanoma
enthalten in:
ESMO open
| 2022
von
Gouda, M.
|
Polivka, J.
|
Huang, H.
| +9
Wird geladen...
4
PIK3CA mutations in plasma circulating tumor DNA predict survival and treatment outcomes in patients with advanced cancers
enthalten in:
ESMO open
| 2021
von
Dumbrava, E.
|
Call, S.
|
Huang, H.
| +18
Wird geladen...
5
Characterization and management of ERK inhibitor associated dermatologic adverse events : analysis from a nonrandomized trial of ulixertinib for advanced cancers
enthalten in:
Investigational new drugs
| 2021
von
Wu, J.
|
Liu, D.
|
Offin, M.
| +15
Wird geladen...
6
Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors : a phase I study
enthalten in:
ESMO open
| 2021
von
Cascone, T.
|
Sacks, R.
|
Subbiah, I.
| +17
Wird geladen...
7
Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers
enthalten in:
Investigational new drugs
| 2021
von
Wu, J.
|
Liu, D.
|
Offin, M.
| +15
Wird geladen...
8
Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers
enthalten in:
Investigational new drugs
| 2021
von
Wu, J.
|
Liu, D.
|
Offin, M.
| +15
Wird geladen...
9
Characterization and management of ERK inhibitor associated dermatologic adverse events: analysis from a nonrandomized trial of ulixertinib for advanced cancers
enthalten in:
Investigational new drugs
| 2021
von
Wu, J.
|
Liu, D.
|
Offin, M.
| +15
Wird geladen...
10
A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies
in:
OncoTargets and Therapy
| 2021
von
Piha-Paul SA
|
Dumbrava EE
|
Nair BC
| +14
Wird geladen...
1
2
3
4
5
6
7
Nächster »
[7]
Filter & Sortierung
Treffer pro Seite
10
20
50
Sortieren
Relevanz
Neueste zuerst
Älteste zuerst
Verfasser
Zeitschriftentitel
Bibliothek
Standort (Printmedien)
Verwandte Substanzen
Verwandte Substanzen werden ermittelt...
Verwandte Erkrankungen/Symptome
Verwandte Erkrankungen/Symptome werden ermittelt...
Verwandte Gene
Verwandte Gene werden ermittelt...
Systematic Reviews
Clinical Studies
Patente
Covid-19/SARS-CoV-2
Exclude Systematic Reviews
Exclude Clinical Studies
Exclude Patents
Medienart
66
Aufsätze
40
Gedruckte Aufsätze
26
E-Artikel
26
E-Ressourcen
Zeitschriftentitel
12
Annals of oncology : official journal of the Eu...
10
Annals of oncology
7
The European journal of cancer / A
4
ESMO open
4
European journal of cancer / EJC Supplements
4
Investigational new drugs
4
Neoplasma
3
BMC cancer
3
Cancer discovery
2
Casopis lekaru ceskych
2
Molecular cancer therapeutics
2
OncoTargets and Therapy
2
Oncology
1
Cancer research
1
Clinical cancer research
1
European journal of cancer (Oxford, England : 1...
1
Gynecologic oncology
1
Journal of vascular and interventional radiology
1
Nature Clinical Practice / Oncology
1
The New England journal of medicine
Alle anzeigen ...
weniger ...
Thema
24
Journal Article
12
Research Support, Non-U.S. Gov't
9
Research Support, N.I.H., Extramural
7
Biomarkers, Tumor
5
Antineoplastic Agents
5
Circulating Tumor DNA
5
Clinical Trial, Phase I
4
Clinical trial
4
Dermatologic adverse events
4
EC 2.7.10.1
4
EC 3.6.5.2
4
ERK inhibitor
4
KRAS protein, human
4
Proto-Oncogene Proteins p21(ras)
4
Ulixertinib
3
BRAF protein, human
3
Class I Phosphatidylinositol 3-Kinases
3
Clinical Trial, Phase III
3
EC 2.7.1.137
3
EC 2.7.11.1
Alle anzeigen ...
weniger ...
Erscheinungszeitraum
10
2020-
47
2010-2019
9
2000-2009
Erscheinungsjahr(e)
Von:
Bis:
Sprache
44
Englisch
2
Tschechisch
Haven't found what you're looking for?
Wird geladen...